Loading...
Market
Story
Johnson & Johnson's Rybrevant Shows Positive Results, 49% Response Rate in Lung and Colorectal Cancer
Sep 14, 2024, 01:48 PM
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) in combination with chemotherapy has shown a positive overall survival trend compared to chemotherapy alone in patients with previously treated EGFR-mutated lung cancer. Additionally, the combination therapy demonstrated a 49 percent overall response rate in metastatic colorectal cancer. The Phase II data from Rybrevant in colorectal cancer suggest that bispecifics may outperform standard monoclonal antibodies, potentially ushering in curative potential. However, the Mariposa-2 combo was described as a 'toxic & expensive arrow' by a #ESMO24 discussant.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Significant reduction in reactions • 25%
Moderate reduction in reactions • 25%
No significant change • 25%
Increase in reactions • 25%
Lung cancer related indication • 25%
Other cancer indication • 25%
Non-cancer indication • 25%
No new approval • 25%
Yes • 50%
No • 50%
Japan • 25%
Canada • 25%
Australia • 25%
None of the above • 25%
Yes • 50%
No • 50%
